These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 29145543)

  • 1. Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.
    Lheureux S; Butler MO; Clarke B; Cristea MC; Martin LP; Tonkin K; Fleming GF; Tinker AV; Hirte HW; Tsoref D; Mackay H; Dhani NC; Ghatage P; Weberpals J; Welch S; Pham NA; Motta V; Sotov V; Wang L; Karakasis K; Udagani S; Kamel-Reid S; Streicher HZ; Shaw P; Oza AM
    JAMA Oncol; 2018 Jul; 4(7):e173776. PubMed ID: 29145543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.
    Mayadev JS; Enserro D; Lin YG; Da Silva DM; Lankes HA; Aghajanian C; Ghamande S; Moore KN; Kennedy VA; Fracasso PM; Schilder RJ
    JAMA Oncol; 2020 Jan; 6(1):92-99. PubMed ID: 31774464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
    JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
    O'Malley DM; Neffa M; Monk BJ; Melkadze T; Huang M; Kryzhanivska A; Bulat I; Meniawy TM; Bagameri A; Wang EW; Doger de Speville Uribe B; Hegg R; Ortuzar Feliu W; Ancukiewicz M; Lugowska I
    J Clin Oncol; 2022 Mar; 40(7):762-771. PubMed ID: 34932394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
    O'Malley DM; Oaknin A; Monk BJ; Selle F; Rojas C; Gladieff L; Berton D; Leary A; Moore KN; Estevez-Diz MDP; Hardy-Bessard AC; Alexandre J; Opperman CP; de Azevedo CRAS; Randall LM; Feliu WO; Ancukiewicz M; Ray-Coquard I
    Gynecol Oncol; 2021 Nov; 163(2):274-280. PubMed ID: 34452745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
    Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
    BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Disis ML; Taylor MH; Kelly K; Beck JT; Gordon M; Moore KM; Patel MR; Chaves J; Park H; Mita AC; Hamilton EP; Annunziata CM; Grote HJ; von Heydebreck A; Grewal J; Chand V; Gulley JL
    JAMA Oncol; 2019 Mar; 5(3):393-401. PubMed ID: 30676622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
    D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
    Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma.
    Boutros C; Chaput-Gras N; Lanoy E; Larive A; Mateus C; Routier E; Sun R; Tao YG; Massard C; Bahleda R; Schwob D; Ibrahim N; Khoury Abboud RM; Caramella C; Lancia A; Cassard L; Roy S; Soria JC; Robert C; Deutsch E
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival with Cemiplimab in Recurrent Cervical Cancer.
    Tewari KS; Monk BJ; Vergote I; Miller A; de Melo AC; Kim HS; Kim YM; Lisyanskaya A; Samouëlian V; Lorusso D; Damian F; Chang CL; Gotovkin EA; Takahashi S; Ramone D; Pikiel J; Maćkowiak-Matejczyk B; Guerra Alía EM; Colombo N; Makarova Y; Rischin D; Lheureux S; Hasegawa K; Fujiwara K; Li J; Jamil S; Jankovic V; Chen CI; Seebach F; Weinreich DM; Yancopoulos GD; Lowy I; Mathias M; Fury MG; Oaknin A;
    N Engl J Med; 2022 Feb; 386(6):544-555. PubMed ID: 35139273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).
    Da Silva DM; Enserro DM; Mayadev JS; Skeate JG; Matsuo K; Pham HQ; Lankes HA; Moxley KM; Ghamande SA; Lin YG; Schilder RJ; Birrer MJ; Kast WM
    Clin Cancer Res; 2020 Nov; 26(21):5621-5630. PubMed ID: 32816895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
    Hong DS; Concin N; Vergote I; de Bono JS; Slomovitz BM; Drew Y; Arkenau HT; Machiels JP; Spicer JF; Jones R; Forster MD; Cornez N; Gennigens C; Johnson ML; Thistlethwaite FC; Rangwala RA; Ghatta S; Windfeld K; Harris JR; Lassen UN; Coleman RL
    Clin Cancer Res; 2020 Mar; 26(6):1220-1228. PubMed ID: 31796521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.
    Naumann RW; Hollebecque A; Meyer T; Devlin MJ; Oaknin A; Kerger J; López-Picazo JM; Machiels JP; Delord JP; Evans TRJ; Boni V; Calvo E; Topalian SL; Chen T; Soumaoro I; Li B; Gu J; Zwirtes R; Moore KN
    J Clin Oncol; 2019 Nov; 37(31):2825-2834. PubMed ID: 31487218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
    Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
    Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
    Santin AD; Deng W; Frumovitz M; Buza N; Bellone S; Huh W; Khleif S; Lankes HA; Ratner ES; O'Cearbhaill RE; Jazaeri AA; Birrer M
    Gynecol Oncol; 2020 Apr; 157(1):161-166. PubMed ID: 31924334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
    Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
    J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
    Rischin D; Gil-Martin M; González-Martin A; Braña I; Hou JY; Cho D; Falchook GS; Formenti S; Jabbour S; Moore K; Naing A; Papadopoulos KP; Baranda J; Fury W; Feng M; Stankevich E; Li J; Yama-Dang NA; Yoo SY; Lowy I; Mathias M; Fury MG
    Gynecol Oncol; 2020 Nov; 159(2):322-328. PubMed ID: 32917410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
    Patel SP; Kim DW; Bassett RL; Cain S; Washington E; Hwu WJ; Kim KB; Papadopoulos NE; Homsi J; Hwu P; Bedikian AY
    Cancer Immunol Immunother; 2017 Oct; 66(10):1359-1366. PubMed ID: 28612140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial.
    Klein O; Kee D; Gao B; Markman B; da Gama Duarte J; Quigley L; Jackett L; Linklater R; Strickland A; Scott C; Mileshkin L; Palmer J; Carlino M; Behren A; Cebon J
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
    Chakravarti N; Ivan D; Trinh VA; Glitza IC; Curry JL; Torres-Cabala C; Tetzlaff MT; Bassett RL; Prieto VG; Hwu WJ
    Melanoma Res; 2017 Feb; 27(1):24-31. PubMed ID: 27768639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.